Enjoei board proposes 10-for-1 reverse stock split to lift share price above BRL 1
Reuters2026/08/11 00:47- Enjoei’s board set an Aug. 31, 2026 extraordinary shareholder meeting to vote on leadership succession, equity plans, and a 10-for-1 share consolidation.
- Board nominated Alexandre Silveira Dias as a permanent director to replace resigning Gregory Louis Reider, subject to shareholder approval.
- Tiê Lima nominated as board chair, Ana Luiza McLaren Moreira Maia e Lima as vice chair; employment and option agreements cleared for CEO-designate Marcos Felipe de Campos Leite.
- Backed supplemental management pay caps of BRL 10.2 million for 2026, BRL 2 million for 2027, BRL 5.91 million for 2026-2030 share-based awards.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Cambria Gold Mines FY26 Q2 net loss narrows to CAD 2.96 million
TRUMP rises nearly 8% in 24 hours, market capitalization reaches $2.037 billions
Electra Therapeutics (ETRA.US) submits US IPO application, leveraging the biotech IPO boom to advance new drug development for immune diseases and cancer.
Electra Therapeutics Inc. has officially filed for an initial public offering (IPO), aiming to leverage the strong IPO performance of the biotechnology sector this year to raise funds for its clinical-stage pipeline of drugs targeting immune-mediated diseases and cancer.
